HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $20 price target.
Stocks · News reference
Rockwell Medical Affirms FY2026 Sales Guidance of $70.000M-$75.000M vs $72.469M Est
Rockwell Medical (NASDAQ:RMTI) affirms FY2026 sales outlook from $70.000 million-$75.000 million to $70.000 million-$75.000 million vs $72.469 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ROCKWELL MEDICAL, INC. (RMTI)
Filed: 2026-08-13 AccNo: 0001628280-26-056470 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Rockwell Medical Q2 Adj. EPS $(0.04) Beats $(0.23) Estimate, Sales $17.780M Miss $17.837M Estimate
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.23) by 82.61 percent. This is a 300 percent decrease over losses of $(0.01) per share from